INT183877

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 5.33
Pain Relevance 0.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (PAF1)
Anatomy Link Frequency
HPAF-II 6
BxPC-3 1
PAF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 26 97.12 Very High Very High Very High
beta blocker 27 88.96 High High
tolerance 9 80.96 Quite High
amygdala 12 79.20 Quite High
medulla 12 65.76 Quite High
fibrosis 7 37.08 Quite Low
Inflammation 14 24.96 Low Low
nMDA receptor 1 16.00 Low Low
Chronic pancreatitis 14 5.00 Very Low Very Low Very Low
Pain 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Heart Rate Under Development 59 99.72 Very High Very High Very High
Myocardial Infarction 37 99.60 Very High Very High Very High
Arrhythmias 2 Under Development 50 99.14 Very High Very High Very High
Adenocarcinoma 357 99.00 Very High Very High Very High
Coronary Artery Disease 10 98.28 Very High Very High Very High
Death 277 98.08 Very High Very High Very High
Cv General 3 Under Development 20 97.12 Very High Very High Very High
Arrhythmia Under Development 33 93.72 High High
Pancreatic Cancer 49 93.36 High High
Clostridium Infection 7 85.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Levels of active Erk and p38 MAPK were assessed in the HPAF-II/GFP-cav-1 transfectants.
Gene_expression (transfectants) of HPAF in HPAF-II
1) Confidence 0.75 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.17 Pain Relevance 0
Using a variation of the colloidal gold assay, we compared untransfected, GFP-vector control and GFP-cav-1 transfected HPAF-II cells in a blue fluorescent bead random migration assay.
Gene_expression (transfected) of HPAF in HPAF-II
2) Confidence 0.65 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.17 Pain Relevance 0
Unexpectedly, the association between cav-1 and RhoC was restored in the HPAF-II/dnRhoC cell line suggesting that inhibition of RhoC activity leads to re-expression of cav-1 protein.
Gene_expression (expression) of HPAF in HPAF-II
3) Confidence 0.65 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.14 Pain Relevance 0
Figure 2B is a comparison of RhoC expression and activation in the BxPC-3 and HPAF-II cell lines.
Gene_expression (expression) of HPAF in HPAF-II
4) Confidence 0.65 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.42 Pain Relevance 0
Figure 3A shows a 57% decrease of active RhoC in the HPAF-II/dnRhoC transfectants compared with the untransfected and vector transfected controls.
Gene_expression (transfectants) of HPAF in HPAF-II
5) Confidence 0.58 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.17 Pain Relevance 0
Next, to directly implicate RhoC in PC cell migration and invasion, we generated stable HPAF-II dominant negative RhoC (dnRhoC) transfectants.
Gene_expression (transfectants) of HPAF in HPAF-II associated with adenocarcinoma
6) Confidence 0.58 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.22 Pain Relevance 0
PD2i was also found to be a statistically significant predictor of AD in the AMI subgroup (relative-risk = 7.39, p ?
Gene_expression (found) of PD2i associated with death
7) Confidence 0.50 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 1.00 Pain Relevance 0.34
These two PD2i patterns each indicate PD2i ?
Gene_expression (patterns) of PD2i
8) Confidence 0.43 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.42 Pain Relevance 0
1.4) was based on our previous retrospective study in patients with nonsustained ventricular tachycardia (VT) (triplets to less than 30-sec runs of VT) in which the separator between the ventricular fibrillation (VF) and nonVF patients was clearly a minimum PD2i score in the 1.21 to 1.40 bin, that is, PD2i ?
Gene_expression (score) of PD2i associated with heart rate under development and arrhythmias 2 under development
9) Confidence 0.43 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.70 Pain Relevance 0.04
Composite RR interval and PD2i results
Gene_expression (results) of PD2i
10) Confidence 0.43 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.67 Pain Relevance 0
What the PD2i measures
Gene_expression (measures) of PD2i
11) Confidence 0.43 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621378 Disease Relevance 0.64 Pain Relevance 0.07
Figure 2B is a comparison of RhoC expression and activation in the BxPC-3 and HPAF-II cell lines.
Gene_expression (expression) of HPAF in BxPC-3
12) Confidence 0.22 Published 2005 Journal Mol Cancer Section Body Doc Link PMC1173138 Disease Relevance 0.42 Pain Relevance 0
The PD2i test can be made with only a 15- to 20-min sample of the resting ECG (ie, >1,000 R-Rs to resolve PD2is < 3.0).
Gene_expression (made) of PD2i
13) Confidence 0.03 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2731023 Disease Relevance 0.20 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox